3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Advanced Solid Tumors
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
talazoparib
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
mCRPC
×
talazoparib
×
Clear all
NCT03395197
2026-04-22
TALAPRO-2
Pfizer
Phase 3
Active not recruiting
1,054 enrolled
21 charts
1 FDA